{"id":68765,"date":"2026-06-23T23:48:27","date_gmt":"2026-06-23T15:48:27","guid":{"rendered":"https:\/\/flcube.com\/?p=68765"},"modified":"2026-06-23T23:48:28","modified_gmt":"2026-06-23T15:48:28","slug":"haisco-pharmaceutical-secures-1-46b-global-licensing-deal-with-nuvectis-for-braf-and-cfb-inhibitor-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68765","title":{"rendered":"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Haisco Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002653:SHE\">SHE: 002653<\/a>) announced an <strong>exclusive global licensing agreement<\/strong> with U.S.-based <strong>Nuvectis Pharma, Inc.<\/strong> for two proprietary pipeline assets: <strong>HSK42360<\/strong> (a BRAF inhibitor) and <strong>HSK39297<\/strong> (a complement factor B inhibitor), with total potential deal value reaching <strong>USD 1.461 billion<\/strong> including upfront payments, milestones, and royalties.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-terms\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront &amp; Near-term Milestones<\/strong><\/td><td>USD 40 million<\/td><\/tr><tr><td><strong>Additional Milestone Payments<\/strong><\/td><td>Up to USD 1.421 billion<\/td><\/tr><tr><td><strong>Royalty Structure<\/strong><\/td><td>Sales-based royalties on net sales<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>USD 1.461 billion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-licensed-asset-territories\" class=\"wp-block-heading\">Licensed Asset Territories<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HSK42360 (BRAF inhibitor):<\/strong> Exclusive rights granted globally <strong>outside Greater China<\/strong><\/li>\n\n\n\n<li><strong>HSK39297 (CFB inhibitor):<\/strong> Exclusive rights granted globally <strong>outside Greater China, Southeast Asia, and India<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-hsk42360-braf-paradoxical-breaker-profile\" class=\"wp-block-heading\">HSK42360 \u2013 BRAF Paradoxical Breaker Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Proprietary, potential <strong>best-in-class BRAF paradoxical breaker inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Dual Action:<\/strong> Inhibits <strong>BRAF V600X mutations<\/strong> while simultaneously <strong>blocking BRAF dimer formation<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Overcomes acquired resistance associated with first-generation BRAF inhibitors across multiple tumor types<\/li>\n\n\n\n<li><strong>CNS Penetration:<\/strong> Demonstrates <strong>excellent central nervous system (CNS) penetration<\/strong>, providing strong potential in both primary brain tumors and brain metastases<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Currently in <strong>Phase I clinical trials<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-hsk39297-complement-factor-b-inhibitor-profile\" class=\"wp-block-heading\">HSK39297 \u2013 Complement Factor B Inhibitor Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Highly potent and selective small-molecule inhibitor of <strong>complement factor B (FB)<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks activation of the <strong>alternative pathway (AP)<\/strong> and <strong>complement amplification loop<\/strong>, suppressing overall complement pathway activity<\/li>\n\n\n\n<li><strong>Indications:<\/strong> Designed to treat diseases mediated by <strong>abnormal complement activation<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong><\/li>\n\n\n\n<li><strong>NDA submitted in China<\/strong> for paroxysmal nocturnal hemoglobinuria (PNH)<\/li>\n\n\n\n<li><strong>Phase II trials<\/strong> ongoing for lupus nephritis<\/li>\n\n\n\n<li><strong>Phase III studies<\/strong> underway for primary IgA nephropathy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Expansion:<\/strong> Enables Haisco to leverage Nuvectis&#8217; international development and commercialization expertise while retaining rights in key Asian markets<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> Provides substantial non-dilutive funding to advance Haisco&#8217;s broader pipeline without equity issuance<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Transfers global development costs and regulatory risks to Nuvectis while maintaining significant upside through milestone and royalty participation<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> The substantial deal value reflects strong confidence in both molecules&#8217; clinical and commercial potential<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This transaction represents one of the largest out-licensing deals by a Chinese pharmaceutical company in 2026, highlighting the growing international recognition of China&#8217;s innovative drug development capabilities. The focus on targeted oncology (BRAF) and immunology (complement pathway) aligns with high-value therapeutic areas commanding premium valuations in global markets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and financial expectations. Actual outcomes may differ materially due to risks including clinical trial results, regulatory decisions, market competition, and achievement of milestone conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eNuvectis\u7b7e\u7f72HSK42360\u548cHSK39297\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eNuvectis\u7b7e\u7f72HSK42360\u548cHSK39297\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-9a4ac531-f62f-4f7e-9d82-93353682f2c9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eNuvectis\u7b7e\u7f72HSK42360\u548cHSK39297\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\">\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eNuvectis\u7b7e\u7f72HSK42360\u548cHSK39297\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u4e0eNuvectis\u7b7e\u7f72HSK42360\u548cHSK39297\u6388\u6743\u8bb8\u53ef\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9a4ac531-f62f-4f7e-9d82-93353682f2c9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,139,24,929],"class_list":["post-68765","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-haisco-pharmaceutical","tag-rare-orphan-disease-drugs","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based Nuvectis Pharma, Inc. for two proprietary pipeline assets: HSK42360 (a BRAF inhibitor) and HSK39297 (a complement factor B inhibitor), with total potential deal value reaching USD 1.461 billion including upfront payments, milestones, and royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68765\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs\" \/>\n<meta property=\"og:description\" content=\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based Nuvectis Pharma, Inc. for two proprietary pipeline assets: HSK42360 (a BRAF inhibitor) and HSK39297 (a complement factor B inhibitor), with total potential deal value reaching USD 1.461 billion including upfront payments, milestones, and royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68765\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T15:48:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-23T15:48:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68765#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68765\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs\",\"datePublished\":\"2026-06-23T15:48:27+00:00\",\"dateModified\":\"2026-06-23T15:48:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68765\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Haisco Pharmaceutical\",\"Rare \\\/ orphan disease drugs\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68765#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68765\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68765\",\"name\":\"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-23T15:48:27+00:00\",\"dateModified\":\"2026-06-23T15:48:28+00:00\",\"description\":\"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based Nuvectis Pharma, Inc. for two proprietary pipeline assets: HSK42360 (a BRAF inhibitor) and HSK39297 (a complement factor B inhibitor), with total potential deal value reaching USD 1.461 billion including upfront payments, milestones, and royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68765#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68765\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68765#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs - Insight, China&#039;s Pharmaceutical Industry","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based Nuvectis Pharma, Inc. for two proprietary pipeline assets: HSK42360 (a BRAF inhibitor) and HSK39297 (a complement factor B inhibitor), with total potential deal value reaching USD 1.461 billion including upfront payments, milestones, and royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68765","og_locale":"en_US","og_type":"article","og_title":"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs","og_description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based Nuvectis Pharma, Inc. for two proprietary pipeline assets: HSK42360 (a BRAF inhibitor) and HSK39297 (a complement factor B inhibitor), with total potential deal value reaching USD 1.461 billion including upfront payments, milestones, and royalties.","og_url":"https:\/\/flcube.com\/?p=68765","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-23T15:48:27+00:00","article_modified_time":"2026-06-23T15:48:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68765#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68765"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs","datePublished":"2026-06-23T15:48:27+00:00","dateModified":"2026-06-23T15:48:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68765"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Haisco Pharmaceutical","Rare \/ orphan disease drugs","SHE: 002653"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68765#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68765","url":"https:\/\/flcube.com\/?p=68765","name":"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-23T15:48:27+00:00","dateModified":"2026-06-23T15:48:28+00:00","description":"Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based Nuvectis Pharma, Inc. for two proprietary pipeline assets: HSK42360 (a BRAF inhibitor) and HSK39297 (a complement factor B inhibitor), with total potential deal value reaching USD 1.461 billion including upfront payments, milestones, and royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68765#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68765"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68765#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68765"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68765\/revisions"}],"predecessor-version":[{"id":68767,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68765\/revisions\/68767"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}